Abstract
We previously described a series of 3(14)-helical beta-peptides that bind the hDM2 protein and inhibit its interaction with a p53-derived peptide in vitro. Here we present a detailed characterization of the interaction of these peptides with hDM2 and report two new beta-peptides in which non-natural side chains have been substituted into the hDM2-recognition epitope. These peptides feature both improved affinity and inhibitory potency in fluorescence polarization and ELISA assays. Additionally, one of the new beta-peptides also binds the hDM2-related protein, hDMX, which has been identified as another key therapeutic target for activation of the p53 pathway in tumors.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Cycle Proteins
-
Cell Line, Tumor
-
Enzyme-Linked Immunosorbent Assay
-
Fluorescence Polarization
-
Humans
-
Nuclear Proteins / chemistry
-
Nuclear Proteins / metabolism*
-
Peptides / chemical synthesis
-
Peptides / chemistry*
-
Protein Structure, Secondary
-
Proto-Oncogene Proteins / chemistry
-
Proto-Oncogene Proteins / metabolism*
-
Proto-Oncogene Proteins c-mdm2 / chemistry
-
Proto-Oncogene Proteins c-mdm2 / metabolism*
-
Tumor Suppressor Protein p53 / chemistry
-
Tumor Suppressor Protein p53 / metabolism
Substances
-
Cell Cycle Proteins
-
MDM4 protein, human
-
Nuclear Proteins
-
Peptides
-
Proto-Oncogene Proteins
-
Tumor Suppressor Protein p53
-
MDM2 protein, human
-
Proto-Oncogene Proteins c-mdm2